Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29453105 | 0.84 | EPHX2 (0.40) | EPHX2PDE2AAKR1B1EPAS1 | |
| SCHEMBL22206764 | 0.84 | EPHX2 (0.40) | EPHX2PDE2AAKR1B1EPAS1 | |
| SCHEMBL29237824 | 0.84 | EPHX2 (0.37) | EPHX2PDE2AAKR1B1 | |
| SCHEMBL2681143 | 0.84 | PDE2A (0.34) | EPHX2PDE2A | |
| SCHEMBL22035479 | 0.80 | AKR1B1 (0.32) | AKR1B1SCD | |
| SCHEMBL22092975 | 0.77 | DGAT1 (0.45) | EPHX2PDE2A | |
| SCHEMBL31145488 | 0.77 | DGAT1 (0.45) | EPHX2PDE2A | |
| SCHEMBL16097407 | 0.76 | L3MBTL1 (0.39) | PDE2A | |
| SCHEMBL21729544 | 0.75 | PDE2A (0.37) | EPHX2PDE2A | |
| SCHEMBL19643157 | 0.75 | L3MBTL1 (0.39) | EPHX2PDE2AAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546374-B2 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-12-27 | — | — | US | disclosed |
| US-8217067-B2 | Antiinflammatory agents, antidepressants, analgesics, purinergic receptor antagonists; neurodegenerative diseases, spinal cord injuries; 1-(2,3-dichlorophenyl)-N-[(2-methylphenyl)methyl]-1H-tetraazol-5-amine | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| US-7723367-B2 | Amino-tetrazoles analogues and methods of use | ABBOTT LABORATORIES (US) | 2010-05-25 | — | — | US | disclosed |
| US-7704997-B1 | Amino-tetrazole analogues and methods of use | ABBOTT LABORATORIES (US) | 2010-04-27 | — | — | US | disclosed |
| US-20080280873-A1 | Biaryl Substituted Pyrazinones as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| US-20080280873-A1 | Biaryl Substituted Pyrazinones as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| US-20080280873-A1 | Biaryl Substituted Pyrazinones as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| US-20080171733-A1 | Amino-Tetrazoles Analogues and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-17 | — | — | US | disclosed |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1747206-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-01-31 | — | — | EP | disclosed |
| EP-1732564-A1 | BIARYL SUBSTITUTED PYRAZINONES AS SODIUM CHANNEL BLOCKERS | Merck & Co., Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | ABBVIE INC. | 2006-03-09 | — | — | US | disclosed |
| WO-2005111003-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005097136-A1 | BIARYL SUBSTITUTED PYRAZINONES AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171733-A1 | Amino-Tetrazoles Analogues and Methods of Use | P2RX7, P2RX2, P2RX5 | EPHX2 1385/4885PDE2A 1960/4885GPR3 173/4885 |
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | P2RX7, P2RX2, P2RX5 | EPHX2 1385/4885PDE2A 1960/4885GPR3 173/4885 |
| US-20080280873-A1 | Biaryl Substituted Pyrazinones as Sodium Channel Blockers | TRPV1, TRPA1, TRPV5 | EPHX2 3038/4885PDE2A 1128/4885GPR3 371/4885 |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | P2RX7, P2RX2, P2RX5 | EPHX2 1385/4885PDE2A 1960/4885GPR3 173/4885 |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | P2RX7, P2RX2, P2RX3 | EPHX2 1355/4885PDE2A 2059/4885GPR3 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.